Multidisciplinary Care of Patients with Inherited Metabolic Diseases and Epilepsy: Current Perspectives

Birutė Tumiene1,2, Mireia del Toro Riera3, Jurgita Grikiniene4, Rūta Samaitiene-Aleknienė4, Rūta Praninskienė4, Ahmad Ardeshir Monavari5,6, Jolanta Sykut-Cegielska7

1Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; 2Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania; 3Pediatric Neurology Department, Unit of Hereditary Metabolic Disorders, Hospital Universitari Vall d’Hebron, Barcelona, Spain; 4Clinic of Children’s Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; 5National Centre for Inherited Metabolic Disorders, Children’s Health Ireland at Temple Street Dublin, Dublin, Ireland; 6University College Dublin, Dublin, Ireland; 7Department of Inborn Errors of Metabolism and Paediatrics, the Institute of Mother and Child, Warsaw, Poland

Correspondence: Birutė Tumiene, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Santariskiu str. 2, Vilnius, LT-06681, Lithuania, Tel +370 614 45026, Email birute.tumiene@santa.lt

Abstract: More than 650 inherited metabolic diseases may present with epilepsy or seizures. These diseases are often multisystem, life-long and induce complex needs of patients and families. Multidisciplinary care involves all stages of disease management: diagnostics, specific or symptomatic, acute and chronic treatments, and integrated care that takes into account not only medical, but also manifold psychosocial, educational, vocational and other needs of patients and their caregivers. Care coordination is indispensable to ensure smooth transitions of care across life and disease stages, including management of emergencies, transition from pediatric to adult services and palliative care. Care pathways are highly diverse and have to find the right balance between highly specialized and locally provided services. While multidisciplinary teams consist of many professionals, a named supervising physician in a highly specialized healthcare setting and a care coordinator are highly important. As the greatest burden of care always falls onto the shoulders of patients and/or families, patient empowerment should be a part of every care pathway and include provision of required information, involvement into common decision-making, patient’s and family’s education, support for self-management, liaison with peer support groups and emotional/psychological support. Due to the rarity and complexity of these diseases, sufficient expertise may not be available in a national healthcare system and cross-border services (virtual or physical) in the recently developed European Reference Networks should be ensured through the proper organization of referral systems in each EU and EEA country. Finally, digital technologies are particularly important in the provision of services for patients with rare diseases and can significantly increase the availability of highly specialized services and expertise.

Keywords: integrated care, transition, care pathways, care coordination, patient empowerment, management of emergencies

Introduction

Following a recent update of the definition and classification of inherited metabolic diseases (IMD), more than 1600 IMDs were described (http://www.iembase.org/).1 Although it is frequently presumed that IMDs are uncommon cause of epilepsy or seizures,2,3 timely diagnosis of these diseases is particularly important for several reasons: 1) As many as 600 (37%) IMDs out of 1616 currently described (as of 22.10.2021, accessed through http://www.iembase.org/) may involve epilepsy or seizures as the main or one of many symptoms (Box 1). Only a subset of these IMDs may be diagnosed through conventional metabolic testing, therefore, their true prevalence may have been underestimated in previous metabolic testing-based studies.4,5 Moreover, novel groups of IMDs have recently been defined (eg, congenital disorders of autophagy, disorders of the synaptic vesicle cycle) and many of these novel diseases may present with epilepsy or seizures;6,7 2) Specific etiologic treatments are being developed for an increasing number of IMDs and it is imperative to diagnose these diseases and institute treatments in time.8,9 Conventional treatments of epilepsy can be ineffective in
some IMDs, while specific etiological treatments (eg, in pyridoxine-dependent epilepsy\textsuperscript{10} may fundamentally improve patient’s prognosis and enable fulfilling life for the patient and his/her family. 3) Even in cases where specific treatments are not available, precise diagnosis of IMD may still be highly beneficial to patients and families as it allows halting diagnostic odyssey and avoidance of further, sometimes invasive testing.\textsuperscript{11} In some cases potentially detrimental treatments may be withheld as in the case of epilepsy due to some mitochondrial diseases where valproates may induce fatal hepatic failure.\textsuperscript{12} Besides, genetic diagnosis gives prognostic information, enables appropriate targeted long-term follow-up, informed reproductive choices for families, inclusion into clinical trials and engagement into patient organizations.\textsuperscript{4,13} In cases of refractory epilepsy, identification of germline mutations in specific genes contraindicates surgery while mutations in other genes do not.\textsuperscript{14} A subset of IMDs is highly amenable to ketogenic dietary treatment.\textsuperscript{15} Generally, diagnosis of IMD is more likely to change management of a patient compared to other genetic diagnoses: in a recent study of 59 patients with early-onset epilepsy who got the genetic diagnosis through whole exome sequencing (12 of them (20%) were diagnosed with IMD), clinical management following genetic diagnosis was changed in 5 patients with IMD (42% of patients with IMD) and 17 patients without IMD (36% of patients without IMD).\textsuperscript{16} Therefore, precise diagnosis of IMD is highly important for further multidisciplinary integrated care of patients.

The vast majority of IMDs that may present with epilepsy or seizures are multisystem, life-long disorders where epilepsy or seizures is just one among many other symptoms. Multidisciplinary care involves all stages of management: diagnostics, acute and chronic treatments, and long-term integrated care for patients with complex needs. Not only medical, but also manifold psychosocial, educational, vocational and other needs of patients and their caregivers must be taken into account.\textsuperscript{17,18} In this narrative review we investigate various aspects of multidisciplinary care and discuss about some key challenges, opportunities and suggestions for the organization of high-quality care services that meet expectations of patients and families and conform to current patient-centered and value-based care principles. Further research on the overall organization of multidisciplinary, integrated care and various aspects of service provision may enable optimization of complex care and, eventually, better outcomes for IMD patients with epilepsy or seizures and their caregivers.

Materials and Methods

We performed literature searches using PubMed and Medline electronic databases using the various combinations of the following search terms: “epilepsy” OR “seizures” AND “inherited metabolic diseases” OR “inborn errors of metabolism” OR “multidisciplinary care” OR “care coordination” OR “transition of care” OR “self-management”. Further searches were informed by references in the publications and related features in PubMed. Searches were limited to English language and included a period of 2010 to current (October 2021) period.

Terms and Definitions

IMD was defined as any primary genetic condition in which alteration of a biochemical pathway is intrinsic to specific biochemical, clinical and/or pathophysiological features.\textsuperscript{1} Multidisciplinary care was defined as a care when professionals from a range of disciplines work together to deliver comprehensive care that addresses as many of the patient’s needs as possible.\textsuperscript{19} Care coordination involves deliberately organizing patient care activities and sharing information among all of the participants concerned with a patient’s care to achieve safer and more effective care.\textsuperscript{20} Care pathways were defined as a complex intervention for the mutual decision-making and organization of care processes for a well-defined group of patients during a well-defined period. Defining characteristics of care pathways include: a) an explicit statement of the goals and key elements of care based on evidence, best practice, and patients’ expectations and their characteristics; b) the facilitation of the communication among the team members and with patients and families; c) the coordination of the care process by coordinating the roles and sequencing the activities of the multidisciplinary care team, the patients and their relatives; d) the documentation, monitoring, and evaluation of variances and outcomes, and e) the identification of the appropriate resources.\textsuperscript{21} Patient empowerment was defined as patient engagement through which individuals and communities are able to express their needs, are involved in decision-making, take action to meet those needs.\textsuperscript{22}
Self-management was defined as the interaction of health behaviors and related processes that patients and families engage in to care for a chronic condition.23

Transitional care was defined as the purposeful, planned movement of adolescents and young adults with chronic physical and medical conditions from child-centered to adult-oriented health care systems.24

Palliative care was defined as the active total care of body, mind and spirit, (as well as) giving support to the family. It begins at diagnosis, and continues regardless of whether or not a patient receives treatment directed at the disease.25

Ultra-rare disease was defined as a disease with a prevalence of <1 per 50,000 persons.26

Seizures were defined as a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain.27

Epilepsy was defined as a disease of the brain defined by any of the following conditions: (1) At least two unprovoked (or reflex) seizures occurring >24 h apart; (2) one unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years; (3) diagnosis of an epilepsy syndrome.28

Epilepsy syndromes were defined as syndromes that have a typical age of seizure onset, specific seizure types and EEG characteristics and often other features which when taken together allow the specific epilepsy syndrome diagnosis.29

Discussion

Inherited Metabolic Diseases Presenting with Epilepsy or Seizures

More than 1600 IMDs are currently on the list of IMD classification http://www.icimd.org/; http://www.iembase.org/,1 600 of them (37% of all described IMDs) may present with epilepsy or seizures (Box 1). All these IMDs are rare or ultra-rare diseases, and various stages of their management require highly-specialized services and expert knowledge that goes beyond those available at primary or secondary healthcare level. IMDs presenting with epilepsy or seizures are highly heterogeneous: although involvement of central nervous system (CNS) leads to the most disabling and life-threatening symptoms, any other body system or tissue may also be affected with frequently multisystem presentation.30,31

CNS involvement in these diseases results in a wide spectrum of symptoms including global developmental delay, autism, behavioral problems and intellectual disability,9 other more common neurological presentations include neurodegenerative and movement disorders.32,33 Epilepsy may be a dominating symptom (eg, pyridoxine-dependent epilepsy)10 and other developmental and epileptic encephalopathies (DEE) due to IMD),34 or a more variable symptom in a subset of all patients with a given disorder (eg, succinic semialdehyde dehydrogenase deficiency).35 In other cases, symptomatic seizures occur only during acute metabolic decompensation or develop as a consequence of brain damage during metabolic crises (eg, organic acidurias).36 Seizures can be amenable to conventional anti-seizure drugs (ASD), although a substantial number of IMDs are associated with severe and treatment-resistant forms of epilepsy, including DEE34 or status epilepticus.37,38 Presentations of IMDs may be highly diverse, but metabolic etiologies should be considered in unexplained neonatal or infantile seizures, refractory seizures, seizures related to catabolic stress (eg, due to fasting, intercurrent illness or surgeries), multisystem presentation, family history or parental consanguinity.39 The first symptoms of IMDs usually develop in children, however, adolescent or adult-onset presentations are being increasingly identified. Treatments of many IMDs have been optimized leading to an increasing number of patients who survive well into adulthood and, on the other hand, with the improvement of genetic diagnostics IMDs adult persons for whom diagnostics was previously not available, can now be studied.40–42 Currently, almost 50% of approximately 33,000 patients in the European Reference Network for IMDs MetabERN are adults.43

Conventional methods for the diagnosis of epilepsy (as seizure semiology, electrophysiological or neuroradiological investigations) may sometimes provide diagnostic clues to IMDs, however, most frequently findings are non-specific.13 Importantly, IMDs may present with any seizure and epilepsy type and any epilepsy syndrome, while some epilepsy-related brain lesions as neuronal migration defects may be due to IMD.44 Precise diagnosis of IMD may be achieved only through metabolic and/or molecular genetic testing that is usually available in specialized laboratories only.4,45

Many IMDs are amenable to specific etiological treatments,9,46 and many new potential personalized therapies are currently at various stages of clinical research and will be presumably translated into clinical practice in coming years.8
Box 1 Genes Associated with Inherited Metabolic Diseases Involving Epilepsy or Seizures as a Symptom

**Disorders of amino acid metabolism:** AASS, ACAD8, ACADSB, ACY1, ADK, ALDH1A1, AMT, ARG1, ASL, ASNS, ASPA, ASS1, AUH, BCKDHA, BCKDHB, CBS, CFS1, DBT, ECSC1, ETHE1, GAD1, GCDH, GLDC, GLS, GLUD1, GLUL, GPT2, HIBCH, IVD, MCCC1, MCCC2, MLYC1, MMUT, MTR, NAGS, NAT8L, OTC, PAH, PCCA, PCCB, PHGDH, PRODH, PSAT1, PSF, PYS, PSC1, SLC1A1, SLC1A2, SLC1A4, SLC2A3, SLC2A5, SLC6A1, SLC6A19, SQOR, SUOX.

**Disorders of carbohydrate metabolism:** ALDOB, EPM2A, FBP1, GCK, GK, GLYT1, GYS1, GYS2, HK1, NMLC1, PC, PCK1, PFKM, PKG1, PRKAG2, RPIA, SLC1A5, SLC2A1, SLC45A1.

**Disorders of fatty acid and ketone body metabolism:** ACADM, ACADS, ACAT1, CPT1A, CPT2, ETFA, ETFB, ETFDH, HADH, HADHA, HADHB, HMGCL, HMGCS2, SLC16A1, SLC25A20.

**Disorders of energy substrate metabolism:** ACO2, DLAT, DLD, FH, GAMT, GATM, IDH2, IDH3A, MCCC1, MCCC2, MLYCD, MMUT, MTR, NAGS, NAT8L, OTC, PAH, PCCA, PCCB, PHGDH, PRODH, PSAT1, PSF, PYS, PYS2, PSC1, SLC1A1, SLC1A2, SLC1A4, SLC2A3, SLC2A5, SLC6A1, SLC6A19, SQOR, SUOX.

**MT-DNA related disorders:** MT-ATP6, MT-ATP8, MT-CO1, MT-CYB, MT-ND1, MT-ND3, MT-ND4, MT-ND5, MT-ND6, MT-TC, MT-TF, MT-TH, MT-TI, MT-TK, MT-TL1, MT-TN, MT-TP, MT-TQ, MT-TR, MT-TS1, MT-TS2, MT-TV, MT-TW.

**Nuclear-encoded disorders of oxidative phosphorylation:** APOPT1, ATP5F1A, ATP5F1D, ATP5MD, BCS1L, COX10, COX14, COX15, COX20, COX4I1, COX6B1, COX8A, CYCI, FASTKD2, FOXRED1, HCCS, LRPPRC, LRM7, NDUF1, NDUF10, NDUF11, NDUF12, NDUFG2, NDUFJ4, NDUFJ5, NDUFV1, NDUFV2, NUBPL, PET100, SCO1, SCO2, SDHA, SDHAF1, SDHAF2, TACO1, TIMMDC1, TMEM70, UQCC2.

**Disorders of mitochondrial cofactor biosynthesis:** BOLA3, COQ2, COQ4, COQ5, COQ8A, COQ8B, COQ9, IBA57, ISCA1, LIAS, LIPT2, NFS1.

**Disorders of mitochondrial DNA maintenance and replication:** DGUOK, MPV17, POLG, POLG2, RRM2B, SAMHD1, TK2, TWNK.

**Disorders of mitochondrial gene expression:** AARS2, CARS2, DARS2, EARS2, FARS2, GFMI, GMF2, GTPBP3, GUF1, HSD17B10, IARS2, KARS1, LARS2, MRPL12, MRPS22, MRPS34, MTFMT, MTO1, NARS2, PAR2, PNPT1, QRS1, RARS2, RMND1, TRT1, TRNT1, TSFM, TUFM, VARS2.

**Disorders of metabolic repair and proofreading:** ACSF3, D2HGDH, L2HGDH.

**Disorders of lipid metabolism:** ABCD1, ACOX1, ALDH3A2, AMACR, BCS1L, CERS1, CERS2, CHKB, CYP27A1, DDHD2, DEGS1, DHCR24, DHCR7, EBP, ELOVL4, FA2H, FARN1, FDF1, FIG4, HSD17B4, HSD3B7, INPP5K, LBR, LSK, MBOAT7, MFS2, MVK, NDKLH, OCR1, PCT1, PEX5, PEX7, PI4KA, PIK3CA, PIK3R2, PLAG2, PLE1, PTE1, SGPL1, SYNJ1.

**Disorders of lipoprotein metabolism:** VLDLR.

**Disorders of nucleobase, nucleotide and nucleic acid metabolism:** AARS1, ADA2, ADAR1, ADAT3, ADS1, AIMP1, AIMP2, AMPD2, ATIC, CAD, CARS1, CLP1, DLD8, DPD1, DPK, EMG1, EPR1, FARS8, FDSJ1, FIS1, IFI1, ITPA, KARS1, LAGE3, LARS1, LARS2, NUSN2, NT3C3A, OSGEP, POLR3A, PRPS1, PRPS2, QARS, RARS, RNASEH2A, RNASEH2B, RNASET2, RPL10, SARD3, SNORD18, TPS3RK, TPRKB, TREV1, TRIT1, TRMT1A, TSEN15, TSEN2, TSEN34, TSEN54, UBTF, UPB1, VARS1, WDR4, YARS1.

**Disorders of tetrpyrrole metabolism:** ALAD, CPOX, HMBS, PPOX, UGT1A1.

**Disorders of nucleobase, nucleotide and nucleic acid metabolism:** AARS1, ADA2, ADAR1, ADAT3, ADS1, AIMP1, AIMP2, AMPD2, ATIC, CAD, CARS1, CLP1, DLD8, DPD1, DPK, EMG1, EPR1, FARS8, FDSJ1, FIS1, IFI1, ITPA, KARS1, LAGE3, LARS1, LARS2, NUSN2, NT3C3A, OSGEP, POLR3A, PRPS1, PRPS2, QARS, RARS, RNASEH2A, RNASEH2B, RNASET2, RPL10, SARD3, SNORD18, TPS3RK, TPRKB, TREV1, TRIT1, TRMT1A, TSEN15, TSEN2, TSEN34, TSEN54, UBTF, UPB1, VARS1, WDR4, YARS1.

**Other disorders of mitochondrial function:** AFG3L2, AIFM1, ATAD3A, CLPB, CLPP, DNAJC19, FBXL4, GCP1, HSD17B4, HSD3B7, INPP5K, LBR, LSS, MBOAT7, MFS2, MVK, NDKLH, OCR1, PCT1, PEX5, PEX7, PI4KA, PIK3CA, PIK3R2, PLAG2, PLE1, PTE1, SGPL1, SYNJ1.

**Disorders of mitochondrial DNA maintenance and replication:** DGUOK, MPV17, POLG, POLG2, RRM2B, SAMHD1, TK2, TWNK.

**Disorders of mitochondrial gene expression:** AARS2, CARS2, DARS2, EARS2, FARS2, GMF2, GMF2, GTPBP3, GUF1, HSD17B10, IARS2, KARS1, LARS2, MRPL12, MRPS22, MRPS34, MTFMT, MTO1, NARS2, PAR2, PNPT1, QRS1, RARS2, RMND1, TRT1, TRNT1, TSFM, TUFM, VARS2.

**Disorders of metabolic repair and proofreading:** ACSF3, D2HGDH, L2HGDH.

**Disorders of lipid metabolism:** ABCD1, ACOX1, ALDH3A2, AMACR, BCS1L, CERS1, CERS2, CHKB, CYP27A1, DDHD2, DEGS1, DHCR24, DHCR7, EBP, ELOVL4, FA2H, FARN1, FDF1, FIG4, HSD17B4, HSD3B7, INPP5K, LBR, LSS, MBOAT7, MFS2, MVK, NDKLH, OCR1, PCT1, PEX5, PEX7, PI4KA, PIK3CA, PIK3R2, PLAG2, PLE1, PTE1, SGPL1, SYNJ1.

**Disorders of lipoprotein metabolism:** VLDLR.

**Disorders of nucleobase, nucleotide and nucleic acid metabolism:** AARS1, ADA2, ADAR1, ADAT3, ADS1, AIMP1, AIMP2, AMPD2, ATIC, CAD, CARS1, CLP1, DLD8, DPD1, DPK, EMG1, EPR1, FARS8, FDSJ1, FIS1, IFI1, ITPA, KARS1, LAGE3, LARS1, LARS2, NUSN2, NT3C3A, OSGEP, POLR3A, PRPS1, PRPS2, QARS, RARS, RNASEH2A, RNASEH2B, RNASET2, RPL10, SARD3, SNORD18, TPS3RK, TPRKB, TREV1, TRIT1, TRMT1A, TSEN15, TSEN2, TSEN34, TSEN54, UBTF, UPB1, VARS1, WDR4, YARS1.

**Disorders of tetrpyrrole metabolism:** ALAD, CPOX, HMBS, PPOX, UGT1A1.
Specific treatments include nutritional or vitamin/ cofactor supplementation therapies, relatively inexpensive and frequently highly effective treatment modalities. Enzyme replacement and small molecule therapies, stem cell and solid organ transplantations, and cell or gene therapies may also provide opportunities of highly effective specific treatments. It is imperative for clinicians to have a sufficient index of suspicion for these diseases in order to identify and diagnose them in time, as early diagnosis and treatments may prevent major neurological sequelae and enable favorable outcomes.

Care Experiences of Patients and Their Families

Although, to the best of our knowledge, there are no studies that specifically investigate care experiences of patients with IMDs that involve epilepsy or seizures and their families, studies of related patient groups (eg, patients with IMDs, early refractory epilepsy or epilepsy associated with intellectual disability) suggest, that both the overall organization of multidisciplinary, integrated care and various aspects of this care (eg, transition of care or care coordination) are insufficient. Fragmented health and social care systems do not meet expectations and needs of patients and families, there is a lack of support in navigating complex care pathways and insufficient communication among professionals and sectors, especially at transition of care points. Due to the scarcity of knowledge and awareness about these rare diseases, patients and families may be insufficiently provided with the necessary information about the disease, its presumed course, prognosis, possible comorbidities, as well as available services and supports, including psychological support and peer support groups. Patient education, empowerment and inclusion into common decision-making is also lacking. In some cases developed informational materials do not meet patients’ and caregivers’ needs in terms of content and form (eg, preferences of web-based information versus written). Importantly, patients’ and families’ needs change along the clinical path of the disease, therefore, they have to be assessed repeatedly and addressed accordingly. Caregivers of children with IMDs relate that these deficiencies are especially burdensome outside the highly-specialized settings, when encountering professionals unfamiliar with the child’s disease. A distinctive feature of rare diseases with metabolic and epileptic emergencies is their unpredictability and often associated uncertainty, that evokes even higher anxiety, depression and other psychological and emotional issues of caregivers. These facts associated with difficulties in decision-making demand a close communication with professionals which is sometimes felt by patients as very difficult. Finally, care organization and quality of services is highly unequal across and sometimes within countries.

| Disorders of organelle biogenesis, dynamics and interactions: | AP1S2, AP3B2, AP3D1, AP4B1, AP4E1, AP4M1, AP4S1, ARCN1, ARFGEF2, BCAP31, COG2, COG4, COG5, COG6, COG7, COG8, COL4A3BP, DNM1L, GOSR2, LYST, MFF, MICS13, MYOSA, PEX1, PEX10, PEX12, PEX13, PEX14, PEX16, PEX19, PEX2, PEX26, PEX3, PEX5, PEX6, PISD, PNPLA8, Rab18, Rab27a, Rab3GAP1, RUBCN, SCYL2, SERAC1, SLC25A46, SPATA5, STAT2, STX11, STXB2, TANGO2, TRAK1, TRAPP1, TRAPPC12, TRAPPC2L, TRAPPC4, TRAPPC6B, TRAPP9, VPS11, VPS13A, VPS13B, VPS4A, YIF1B. |
| Disorders of complex molecule degradation: | AGA, ARSA, ASAH1, ASAH1, ATP13A2, CLN3, CLNS, CLN6, CLN8, CTSA, CTSO, CTSE, DEMAACS, EPACS, FUCAI, GALC, GBA, GLA, GLB1, GM2A, GNS, GRN, HEXA, HEXB, HGSNAT, IDS, KCTD7, MANBA, MFSDB, NAGA, NAGLU, NEU1, NPC1, NPC2, PPT1, PSAP, SACRB2, SGSH, SMPD4, SNX14, SPG11, SUMF1, TECPR2, TPP1, WDR45. |
| Disorders of vitamin and cofactor metabolism: | ALDH7A1, ALPL, ATD, DHPR, DLPLR, GCH1, GPHN, HCFC1, HLCS, LMBRD1, MMMAA, MMACHC, MMADHC, MADC1, MOC51, MOC52, MTHFD1, MTHFR, MTHFS, MTRR, NAXD, NAXE, NNT, PANK2, PLPBP, PNPO, PTS, QDPR, SLC19A2, SLC19A3, SLC25A19, SLC25A42, SLC46A1, SLC5A6, SPR, TP1. |
| Disorders of trace elements and metals: | ATP7A, ATP7B, CCS, FTL, SEPSEC5, SLC33A1, SLC39A8. |
| Neurotransmitter disorders: | ABAT, ALDH5A1, ATAD1, CLTC, DBH, DNAJC6, DNM1, DYNC1H1, GABBR2, GABRA1, GABRA1, GABRB2, GABBR3, GABRG2, GLRA1, GLRB, GRI2, GRI3, GRI4, GRIN1, GRIN2B, GRIN2D, GRM1, GRM1, IL1RAPL1, KIF1A, KIF5A, KIF5C, PRTT2, SLC18A2, SLC6A5, SNAP25, SNAP29, STX1B, STXB2, SV2A, SYN1, TBC1D24, TH, VAMP2. |
| Endocrine metabolic disorders: | ABCCB, AKT2, HNF1B, KCNJ11, MC2R. |

Note: the classification of IMDs presented according to Ferreira et al. [http://www.icimd.org/; http://www.iembase.org/].
The Goals of Multidisciplinary Care

Due to their multisystem, frequently life-long nature, IMDs that involve epilepsy or seizures usually induce complex long-term needs of patients and their families. The goals of integrated, multidisciplinary care are to place patients and their families at the center of care services planning in order to fully respond to their needs, to address holistically not only health-related but also other (psychological, social, educational, vocational) issues, and to ensure high-quality, accessible and effective services. Summarized goals of integrated, multidisciplinary care for patients with IMDs that involve epilepsy or seizures are presented in Box 2.

Care pathways for these diseases are highly complex and diverse (Figure 1) due to several reasons: 1) Heterogeneity of IMDs that may present with epilepsy or seizures; 2) Diversity in health systems’ organization and available expertise; 3) Patient and family-related factors (eg, rural vs urban living place or willingness to engage into self-management). Healthcare pathway of any rare disease consists of highly-specialized and less specialized services that may variably involve diagnostics, specific and symptomatic treatments, surveillance, rehabilitation, palliative care, cross-border care, patient empowerment, social and community services. Highly-specialized care services for rare diseases are usually provided in the Centers of Excellence (CoE) with sufficient expertise and infrastructural resources (as equipment and multidisciplinary teams of experts). These services are usually expensive, centralized and provided far away from patient’s home, therefore, it is highly important to find the right balance between highly-specialized and local services: in all cases where services may be safely provided locally or require continuous provision (eg, psychological and social support), they have to be provided closer to patient’s home, while ensuring appropriate specialized support when needed, empowerment of local care providers, patients and their families, and effective communication among all care providers.

Comprehensive patient care includes not only healthcare services at different levels of the health system, but also other services to meet the complex needs of patients and their families, including psychological, social, educational and vocational issues, all of which pose significant challenges for care coordination. While general practitioners usually lack time, knowledge and resources to ensure multipronged care coordination for patients with rare diseases, (specialist) nurse coordinators or case managers at the CoE and/or at the primary care level are uniquely positioned to provide appropriate care coordination and management of transitions of care. Trusting patient-provider relationship between nurses and patients/families supports active communication and allows identification of priorities and barriers for integrated care and self-management, enables holistic, proactive management, continuity of care and improved patient outcomes.

Patients with IMDs involving epilepsy or seizures are highly active healthcare users with complex trajectories across care systems and multiple transitions of care across life and disease stages (eg, transition from pediatric to adult services or transition to palliative care). Patients and families face particular challenges at these transition points. Hence, these transitions have to be anticipated, planned, proactively prepared and discussed with the family and care providers.

IMDs involving epilepsy or seizures frequently present with epilepsy or metabolic decompensation-related emergencies, where timely treatments may determine patient’s outcomes. Management of these emergencies evoke particular challenges for families and needs particular consideration from the side of professionals: patients and their families must

---

Box 2 The Goals of Multidisciplinary Care in IMD Patients with Epilepsy or Seizures

- Address the needs of patients with complex care needs and their families in a holistic, comprehensive, family-centered way.
- Find the right balance between highly-specialized and locally provided services in the individual patient care plans.
- Ensure proper care coordination and communication between families and caregivers through the involvement of (specialist) nurse coordinators or case managers.
- Ensure proper management of care transitions by giving special consideration to all life stage-related (eg, transition from pediatric to adult services, pregnancy and perinatal care) and disease stage-related (eg, transition to palliative services) transitions.
- Ensure proper management of emergencies (including those related to metabolic decompensation and/or epilepsy-related emergencies).
- Provide multipronged empowerment of patients and families, including provision of required information, involvement into common decision-making, education, support for self-management, liaison with peer support groups and emotional/psychological support.
- Exploit international collaboration (in particular ERNs) and digital technologies for accessible, cost-effective and high-quality care.
be able to recognize the first signs of an imminent or occurring emergency, have predefined plans for immediate action (eg, oral emergency regimens for nutritional therapies, emergency seizure protocols) and knowledge on how to monitor the patient’s condition, when and where to go for emergency care. These plans must also include 24h/7 days contacts for emergency specialist assistance. In some cases, the patient first goes to the nearest hospital; in such cases, it is necessary to ensure proper communication between healthcare providers and transfer of samples or patients to highly-specialized institutions when required.36,50 Widespread availability of evidence-based emergency protocols is highly important; through international collaboration involving MetabERN, generic emergency protocols for patients with fasting intolerance in eight languages and an on-line tool for generating protocols for individual patients were developed (https://www.emergencyprotocol.net/).59

The greatest burden of care for IMDs that involve epilepsy or seizures always falls on the shoulders of patients and/or families, therefore, each care pathway must include empowerment that must be family-centered.60 A lack of consideration of family’s needs, including not only direct caregivers but also other family members (eg, siblings) harms their ability to provide effective care and may have detrimental effects on patient’s outcomes and wellbeing of the whole family.61 Depending on disease, organization of care in a given country and patient/ family-related factors, empowerment includes provision of required information, involvement into common decision-making, patient’s and family’s education, support for self-management, liaison with peer support groups and emotional/ psychological support.18,48,52,62 Self-management is critical for individuals with epilepsy and their caregivers in order to maintain optimal physical, cognitive, and emotional health, especially in cases of refractory epilepsy or handling such challenging treatments as ketogenic diets.63 Although high benefits of these interventions were demonstrated,64–66 their implementation is still insufficient and requires considering many factors at the person, program, and systems levels.67

International collaboration is indispensable in addressing various aspects of highly-specialized care for rare diseases, therefore, 24 European Rare Diseases Networks (ERNs) for rare and complex diseases were launched in 2017.58 These ERNs provide virtual and physical cross-border services not available in patient’s country of origin, moreover, they develop highly required resources for multidisciplinary, integrated care including clinical practice guidelines, educational programmes, recommendations and tools for integrated multidisciplinary care.43,57 Patients with IMDs that involve epilepsy or seizures may require services of several ERNs: MetabERN was developed for patients with IMDs, EpiCARE

Figure 1 Care pathways for IMD patients with epilepsy or seizures.
is for rare epilepsies, ERN-RND is for rare neurological disorders, and TransplantChild may be required in cases where there is a need for liver, stem cell or other transplantations. The accessibility of ERNs must be ensured through the proper organization of care pathways and referral systems towards ERNs. 

Digital technologies have paved the ways for innovative eHealth services, including teleconsultations for patients and professionals, electronic tools for patient monitoring, self-management and education, and more. Although these services are particularly important for patients with rare diseases and can significantly increase the availability of highly-specialized services and expertise, they are often not properly organized, regulated and reimbursed. The pandemic significantly increased the deployment and use of these services across all healthcare areas, including epilepsy care. 

These achievements are expected to be sustained and exploited for the benefit of patients and their families in the post-pandemic period. Besides, recent explosive spread of digital communication technologies enables liaison among rare disease patients and families dispersed across countries and continents and formation of peer support groups that may provide highly required emotional and practical support and advices, empowerment, advocacy and decrease the feelings of abandonment and isolation. Therefore, impact of digital technologies on service provision and outcomes should be evaluated and exploitation of these technologies along the entire care pathway where required should be encouraged.

Life and Disease Stage-Related Issues

Neonatal Screening

Many IMDs involving epilepsy or seizures are included into neonatal screening programs when they have specific treatments that can improve significantly the prognosis. According to global standards, patients diagnosed through neonatal screening are usually provided with the full range of services that have a big impact on prognosis and quality of life, from screening to diagnosis, institution of treatment, monitoring, and long-term, multidisciplinary management. However, some newborns may develop acute symptoms before the results of neonatal screening are obtained, lists of screened IMDs differ among countries, and only a subset of all IMDs presenting with epilepsy or seizures are suitable for neonatal screening. It is therefore essential for neonatologists to know what diseases are being screened for in their country and where to get the information on IMD screening, diagnostics and expert advice on emergency treatment.

IMDs with Epilepsy or Seizures in Infancy

In some infantile-onset epilepsy syndromes, a considerable subset of patients is diagnosed with IMDs: eg, IMDs have been found in 3% to 22% of infants with West syndrome. Precise genetic diagnosis in these patients may not only enable specific etiological treatments, but also provide prognostic information and guidance for antiseizure treatment. Impact on psychomotor development and cognitive function may vary between some milder developmental encephalopathies to severe epileptic encephalopathies. Clinicians must tailor care towards individual needs and realistic expectations for each affected person; those with developmental encephalopathies are unlikely to gain from aggressive antiseizure medication whilst those with epileptic encephalopathies will gain.

Pediatric to Adult Transition

Transition to adult care represents a vulnerable time in the life of a patient and his/her family. Transition as a purposeful and planned process should address manifold medical, psychosocial, educational, and vocational needs of adolescent and young adult patients as they move from a pediatric to an adult model of care. At the very least, it involves coordination of care between care providers to ensure that the adult providers have sufficient medical and other related information about the patient and his/her family and competence to provide optimal disease management. As much as it is possible, patients should acquire knowledge and skills in the domains of self-care, healthcare decision-making, and self-advocacy in such a way that will prepare them to increase their agency surrounding their healthcare needs. In children with IMDs that involve epilepsy or seizures the primary care provider is usually either pediatric neurologist or metabolic pediatrician. While in transition from pediatric to adult neurologist the largest problem may be excessive anxiety of patients and/or families that is completely resolved with the proper organization of transition, transition among the specialists of metabolic medicine is frequently complicated due to the lack of specialists for adult IMDs. According to the survey of the ERN for IMDs MetabERN, in most European countries transition of pediatric patients and
services for adults with IMDs are insufficiently organized. Due to the inherent phenotypic variability of adult IMDs dependent not only from genotype, but also due to the effect of environmental factors, ontogenetic changes and aging and lack of knowledge on many aspects of IMDs associated with prolonged survival and novel treatments (eg, late adverse effects of interventions and definition of new natural histories), the field of adult IMDs is still developing. 

**Pregnancy and Perinatal Care**

An increasing number of females with IMDs that may present with epilepsy or seizures enter reproductive age. Pregnancy and perinatal care-related issues in this group of women are dual and involve: 1) IMD-related issues, eg disease effects on fertility, teratogenic effects of a disease (as phenylketonuria) or medicines, challenges of nutritional treatments and metabolic control, worsening of an underlying maternal IMD due to pregnancy, special recommendations for breastfeeding and IMD effects on labour (as skeletal dysplasia in mucopolysaccharidoses). Some IMDs of intermediary metabolism may present for the first time or exacerbate during the perinatal period (eg, urea cycle defects). 2) epilepsy and ASD treatment-related issues, including teratogenic effects of some ASD, seizure control during the pregnancy and in the perinatal period and other associated issues. Therefore, obstetricians – gynecologists have to be involved into multidisciplinary teams for the management of females with IMDs.

**Palliative Care**

Patients with life-limiting or life-threatening conditions require timely and family-centered palliative care, especially in a pediatric setting. In medical terms, palliative care aims to achieve pain and symptom management, enhanced dignity and quality of life for the patients. Though comfort is often the most common goal identified, symptom identification and treatment remains challenging in nonverbal children with neurological impairments. Besides, in IMDs symptom burden is usually high with neurologic, respiratory and gastrointestinal symptoms being the most frequent and most of those being difficult to treat or even intractable. Another issue in IMDs, pertinent to any rare disease, is a lack of knowledge and inherent uncertainty about prognosis and medical interventions that may complicate decision-making process. Noteworthy, a high number of children with metabolic diseases die in intensive care units. In these cases, an integrated model of care that combines pediatric intensive care and primary pediatric palliative care depending on the disease trajectory might be a fundamental component of the best available standard of care.

Not only medical, but also ever changing social, psychological, emotional and spiritual needs of the family beyond what the primary care team can provide should be addressed. Therefore, palliative care should be planned in advance, ideally from the moment of diagnosis, and is best delivered in a team committed to family centered care and open and reflective practice throughout the journey of a child’s illness and death, including bereavement period. Quality of relationship and inclusion of a patient and his/her family into a common decision-making are the core elements of palliative care. Families and professionals should also acknowledge the unique experiences and needs of siblings, include siblings in medical conversations and care plans when appropriate, and connect siblings to resources for informational and emotional support.

In some cases, diagnosis of an IMD is only achieved post-mortem. Without a clear diagnosis the families find themselves in a very precarious situation, not least regarding end-of-life decisions. For both caregivers and health care professionals, it may be difficult to even consider palliative care because the course of the disease is not predictable. Additionally, the lack of a diagnosis raises uncertainty about family planning and the risk of recurrence in future children. In spite of these uncertainties, patients and families have the same rights to receive optimized and symptom-adapted palliative care.

**Core and Extended Multidisciplinary Team**

Due to the complexity and rarity of IMDs, general practitioners (GPs) are usually unable to provide all the necessary information, services, and support, therefore, it is highly important for patients and families to have a named physician supervising them in a highly-specialized setting and a multidisciplinary team that encompass both local/regional and
The specialty of this physician depends on the nature of the disease: where epilepsy or seizures is just one of many other symptoms or occur only during acute metabolic decompensation, a supervising physician is usually a metabolic pediatrician or a specialist of adult IMDs. In some countries, specialty of metabolic pediatrician is not formalized, while in most countries specialists of adult IMDs are not available or lacking; in these cases functions of supervising highly-specialized physician may be assumed by geneticists or physicians of other specialties. When the predominant symptom of IMD is epilepsy, the supervising highly-specialized physician is usually a pediatric or adult neurologist or epileptologist. These specialists - A metabolic pediatrician or other specialist in metabolic diseases, a pediatric or adult neurologist (epileptologist) - usually lead a whole multidisciplinary team that is ideally based in a dedicated CoE. The multidisciplinary team consists of core members providing the main services to patients and families: in the IMD department, these may include laboratory specialists from biochemical genetic and molecular genetics laboratory, geneticists, dietician, specialized nurse or other care coordinator, neonatologist and intensive care specialist, rehabilitation specialists, psychologists, social workers and play specialist/therapist. In the epilepsy department, the multidisciplinary core team usually consists of laboratory specialists, neuroradiologist, neurophysiologist, neurosurgeon. If necessary, the core team is complemented by other extended team specialists, eg obstetrician-gynecologist, physicians of other specialties, pharmacist, etc. The CoE for rare diseases usually carry out not only provision of highly-specialized healthcare services but also education and research and these additional functions also determine the composition of the multidisciplinary team. There is a need for staff to manage rare disease registries and biobanks, to administer research projects, to conduct clinical trials, to provide education and training and to collaborate with various research and educational institutions.

All multidisciplinary team members follow the same clinical practice guidelines (CPGs) or other evidence-based resources, develop and implement individual patient care plans, therefore, it is highly important to ensure proper communication and collaboration among the entire team. In addition, appropriate team’s communication with GPs, other care providers across various levels of health and social care systems and appropriate involvement of patients and families are essential, hence, the role of a specialist nurse coordinator or other care coordinator is indispensable.

Multidisciplinary care should also involve primary care and community level: many long-term mental health, physical therapy and rehabilitation, social services for patients and families, services to address educational and vocational issues are inevitably provided at a primary or community level.

**Organization of Services Along the Care Pathway**

Due to the heterogeneity, multisystem nature and complexity of IMDs, the need for highly-specialized services and expertise, and complex care pathways that cross various health system levels, sectoral and sometimes even national
borders, the organization of services for patients with IMDs involving epilepsy or seizures and their families is a challenging task. Although these patients are highly active users of care services and their expectations and needs often remain unmet, very little data for evidence-based governance and principles of care organization are available.\textsuperscript{53,78} While diagnostic and treatment services are frequently provided simultaneously, precise genetic diagnosis usually establish a crucial landmark for the management of these patients.

**Diagnostics**

Diagnosis of IMDs requires sufficient knowledge and experience and is almost invariably obtained through the highly-specialized laboratory testing. GPs and local healthcare providers typically have neither the expertise nor the resources to diagnose IMD. Unfortunately, the primary healthcare level, which is often the first medical contact point for any patient, often lacks sufficient awareness and index of suspicion for rare diseases and health system literacy on where to refer the patient for specialized services.\textsuperscript{87–89} IMDs are implicated with an additional diagnostic urgency due to the fact that many of them have specific etiological treatments. In order to ensure timely diagnosis and treatment and to reduce diagnostic odyssey, it is necessary to properly organize care pathways and referrals systems towards CoE and ERNs in health systems and to increase IMD awareness and education among care providers.\textsuperscript{53}

**Treatments and Long-Term Surveillance**

Once a precise diagnosis has been established, individual patient’s care plan must be developed that is not only evidence-based but also meets the individual needs of the patient and his or her family. Unfortunately, CPGs for rare diseases are very scarce,\textsuperscript{90} while the awareness of and implementation of existing guidelines is clearly deficient and highly unequal across countries.\textsuperscript{91} Fortunately, ERNs are currently intensively working on the development of novel CPGs for rare diseases and implementation of existing ones.

Depending on the nature of the disease and other factors (such as health system organization, available expertise and resources at primary and local level, patient and family empowerment, etc.), the individual care plans should include initial and follow-up examinations (laboratory and instrumental testing, consultations of specialists), disease monitoring, management of emergencies, family support, genetic counseling and testing, and expected transition points across illness and life stages.

**Conclusion**

Due to the heterogeneity, multisystem nature and complexity of IMDs, the need for highly-specialized services and expertise, and complex care pathways that cross various health system levels, sectoral and sometimes even national borders, the organization of services for patients with IMDs involving epilepsy or seizures and their families is a challenging task. Multidisciplinary care should place patients and their families at the center of care services planning and to respond to their complex needs, including not only health-related but also other (psychological, social, educational, vocational) issues.

**Acknowledgments**

This work was supported (not financially) by the European Reference Networks: European Reference Network on hereditary metabolic disorders (MetabERN). This ERN is co-funded by the European Union within the framework of the Third Health Program “ERN-2016—Framework Partnership Agreement 2017–2021”.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Ferreira CR, Rahman S, Keller M, et al. An international classification of inherited metabolic disorders (ICIMD). \textit{J Inherit Metab Dis}. 2021;44(1):164–177. doi:10.1002/jimd.12348
2. Gkampeta A, Pavlou E. Infantile spasms (West syndrome) in children with inborn errors of metabolism: a review of the literature. \textit{J Child Neurol}. 2012;27(10):1295–1301. doi:10.1177/0883073812448532
3. Dulac O, Plecko B, Gataullina S, et al. Occasional seizures, epilepsy, and inborn errors of metabolism. *Lancet Neurol.* 2014;13(7):727–739. doi:10.1016/S1474-4422(14)70110-3

4. Tumienė B, Peterlin B, Mäver A, et al. Contemporary scope of inborn errors of metabolism involving epilepsy or seizures. *Metab Brain Dis.* 2018;33(6):1781–1786. doi:10.1007/s11011-018-0288-1

5. Kwon JM. Testing for inborn errors of metabolism. *Continuum.* 2018;24(1):37–56. doi:10.1212/CON.0000000000000563

6. Ebrahimi-Fakhari D, Saffari A, Wahlster L, et al. Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism. *Brain.* 2016;139(Pt 2):317–337. doi:10.1093/brain/awv371

7. Cortes-Saladelafont E, Tristán-Noguero A, Artuch R, et al. Diseases of the synaptic vesicle: a potential new group of neurometabolic disorders affecting neurotransmission. *Semin Pediatr Neurol.* 2016;23(4):306–320. doi:10.1016/j.spen.2016.11.005

8. Stockler-Ipsiroglu S, Potter BK, Yuknis V, et al. Developments in evidence creation for treatments of inborn errors of metabolism. *J Inherit Metab Dis.* 2021;44(1):88–98. doi:10.1002/jimd.12315

9. Hoytema van Koninjenburg EMM, Wortmann SB, Koellewijn MJ, et al. Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app. *Orphanet J Rare Dis.* 2021;16(1):170. doi:10.1186/s13023-021-01727-2

10. Wilson MP, Plecko B, Mills PB, et al. Disorders affecting vitamin B6 metabolism. *J Inherit Metab Dis.* 2019;42(4):629–646. doi:10.1002/jimd.12060

11. Hoelz H, Herdl C, Gerstl L, et al. Impact on clinical decision making of next-generation sequencing in pediatric epilepsy in a tertiary epilepsy referral center. *Cln EEG Neurosci.* 2020;51(1):61–69. doi:10.1177/1550059419876518

12. Hynynen J, Komulainen T, Tukiainen E, et al. Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. *Liver Transpl.* 2014;20(11):1402–1412. doi:10.1002/hep.23965

13. Van Karnebeek CDM, Sayson B, Lee JYJ, et al. Metabolic evaluation of epilepsy: a diagnostic algorithm with focus on treatable conditions. *Front Neurol.* 2018;9(3):1016. doi:10.3389/fneur.2018.01016

14. Guerrini R, Balestrini S, Wirrell EC, et al. Monogenic epilepsies: disease mechanisms, clinical phenotypes, and targeted therapies. *Neurology.* 2021;97(17):817–831. doi:10.1212/WNL.0000000000012744

15. Gavrîlović C, Rho JM. Metabolic epilepsies amenable to ketogenic therapies: indications, contraindications, and underlying mechanisms. *J Inherit Metab Dis.* 2021;44(1):42–53. doi:10.1002/jimd.12283

16. Demos M, Guella I, DeGuzman C, et al. Diagnostic yield and treatment impact of targeted exome sequencing in early-onset epilepsy. *Front Neurol.* 2019;10:434. doi:10.3389/fneur.2019.00434

17. Khangura SD, Tingley K, Chakraborty P, et al. Child and family experiences with inborn errors of metabolism: a qualitative interview study with representatives of patient groups. *J Inherit Metab Dis.* 2016;39(1):139–147. doi:10.1054/jimd.2016.03625

18. Nevin SM, Wakefeld CE, Schlisra CE, et al. The information needs of parents of children with early-onset epilepsy: a systematic review. *Epilepsy Behav.* 2020;112:107382. doi:10.1016/j.yebeh.2020.107382

19. Mitchell GK, Tieman JJ, Shelby-James TM. Multidisciplinary care planning and teamwork in primary care. *Med J Aust.* 2008;188(S8):S61–S64. doi:10.5698/1326-5377.2008.tb01747.x

20. Agency for health care research and quality. Available from: https://www.ahrq.gov/icepcr/care/coordination.html. Accessed March 18, 2022.

21. Schrijvers G, van Hoon A, Huiskes N. The care pathway: concepts and theories: an introduction. *Int J Integr Care.* 2012;12(6):e192. doi:10.5334/ijic.812

22. De Santis M, Hervas C, Weinman A, et al. Patient empowerment of people living with rare diseases. Its contribution to sustainable and resilient healthcare systems. *Ann Int Super Sanita.* 2019;55(3):283–291. doi:10.4415/ANN_19_03_15

23. Modi AC, Pai AL, Hommel KA, et al. Pediatric self-management: a framework for research, practice, and policy. *Pediatrics.* 2012;129(2):e473–e485. doi:10.1542/peds.2011-1635

24. Blum RW, Garell D, Hodgman CH, et al. Transition from child-centered to adult health-care systems for adolescent with chronic conditions. A position paper of the Society for Adolescent Medicine. *J Adolesc Health.* 1993;14:570–576. doi:10.1016/1054-139X(93)90143-D

25. World Health Organization. Palliative care. Available from: https://www.who.int/health-topics/palliative-care. Accessed March 18, 2022.

26. NICE Citizens Council. *Ultra Orphan Drugs.* Citizens Council Reports No. 4. London: National Institute for Health and Care Excellence (NICE); 2004.

27. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia.* 2005;46(4):470–472. doi:10.1111/j.0013-9580.2005.66104.x

28. Fisher RS, Acvedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. *Epilepsia.* 2014;55(4):475–482. doi:10.1111/epi.12550

29. International league against epilepsy. Epilepsy Syndromes. Available from: https://www.epilepsydiagnosis.org/syndrome/epilepsy-syndrome-groupoverview.html. Accessed March 18, 2022.

30. Hwang WJ, Lim HH, Kim YM, et al. Pancreatic involvement in patients with inborn errors of metabolism. *Orphanet J Rare Dis.* 2021;16(1):37. doi:10.1186/s13023-021-01685-9

31. Santamaría F, Montella S, Mirra V, et al. Respiratory manifestations in patients with inherited metabolic diseases. *Eur Respir Rev.* 2013;22(130):437–453. doi:10.1183/09059180.0008012

32. Warmerdam HAG, Termeulen-Ferreira EA, Tseng LA, et al. A scoping review of inborn errors of metabolism causing Progressive Intellectual and Neurologic Deterioration (PIND). *Front Neurol.* 2020;11:369. doi:10.3389/fneur.2019.01369

33. Ebrahimi-Fakhari D, Van Karnebeek C, Münnich A. Movement disorders in treatable inborn errors of metabolism. *Mov Disord.* 2019;34(5):598–613. doi:10.1002/mds.27568

34. Salar S, Moshe SL, Galanopoulou AS. Metabolic etiologies in West syndrome. *Epilepsia Open.* 2018;3(2):134–166. doi:10.1002/epio.12102

35. Pearl PL, DiBacco ML, Papadelis C, et al. Sucinonic semialdehyde dehydrogenase deficiency: review of the natural history study. *J Child Neurol.* 2021;36(8):883073820981262. doi:10.1177/0883073820981262

36. MacNeill EC, Walker CP. Inborn errors of metabolism in the emergency department (undiagnosed and management of the know). *Emerg Med Clin North Am.* 2018;36(2):369–385. doi:10.1016/j.emc.2017.12.014

37. Bhattachar M, Shorvon S. Genetic mutations associated with status epilepticus. *Epilepsy Behav.* 2015;49:104–110. doi:10.1016/j.yebeh.2015.04.013
38. Guerrini R, Parrini E, Marini C, et al. What is the role of next generation sequencing in status epilepticus? Epilepsy Behav. 2019;101(Pt B):106373. doi:10.1016/j.yebeh.2019.06.017
39. Almannai M, Al Mahmoud RA, Mekki M, et al. Metabolic seizures. Front Neurol. 2021;12:640371. doi:10.3389/fneur.2021.640371
40. Stepien KM, Geberhiwot T, Hendrikz CJ, et al. Challenges in diagnosing and managing adult patients with urea cycle disorders. J Inherit Metab Dis. 2019;42(6):1136–1146. doi:10.1002/jimd.12096
41. Ahrens-Nicklas RC, Slap G, Ficicioglu C. Adolescent presentations of inborn errors of metabolism. J Adolesc Health. 2015;56(5):477–482. doi:10.1016/j.jadohealth.2015.01.008
42. Gariani K, Nascimento M, Superti-Furga A, et al. Clouds over IMD? Perspectives for inherited metabolic diseases in adults from a retrospective cohort study in two Swiss adult metabolic clinics. Orphanet J Rare Dis. 2020;15(1):210. doi:10.1186/s13023-020-01471-z
43. Stepien KM, Kiec-Wilk B, Lampé C, et al. Challenges in transition from childhood to adulthood health care in rare metabolic diseases: results from the first multi-center European survey. Front Med. 2021;8:652358. doi:10.3389/fmed.2021.652358
44. Schiller S, Rosewich H, Grünewald S, et al. Inborn errors of metabolism leading to neuronal migration defects. J Inherit Metab Dis. 2020;43(1):145–155. doi:10.1002/jimd.12194
45. Lee JY, Wasserman WW, Hoffmann GF, et al. Knowledge base and mini-expert platform for the diagnosis of inborn errors of metabolism. Genet Med. 2018;20(1):151–158. doi:10.1038/gim.2017.108
46. Sirrs SM, Lehman A, Stockler S, et al. Treatable inborn errors of metabolism causing neurological symptoms in adults. Mol Genet Metab. 2013;110(4):431–438. doi:10.1016/j.ymgep.2013.10.002
47. Tseng LA, Sowerbut C, Lee JYJ, et al. P4 medicine for epilepsy and intellectual disability: nutritional therapy for inherited metabolic disease. Emerg Top Life Sci. 2019;3(1):75–95. doi:10.1042/ETLS20180180
48. Robertson J, Baines S, Emerson E, et al. Service responses to people with intellectual disabilities and epilepsy: a systematic review. J Appl Res Intell Disabil. 2017;30(1):1–32. doi:10.1111/jar.12228
49. Rajasekar P, Gannavarapu S, Napier M, et al. Parental psychosocial aspects and stressors involved in the management of inborn errors of metabolism. Mol Genet Metab Rep. 2020;25:100654. doi:10.1016/j.ymgmr.2020.100654
50. Tschamper MK, Systad S. Rare, epilepsy-related disorder including intellectual disability - a scoping review of caregivers' identified information needs. J Intellect Disabil. 2021;17446295211002348. doi:10.1017/jid.2021.284
51. Cavaleri S, Marchiò M, Bondi M, Biagioni G. Assessing caregiver informative materials on the ketogenic diet in Italy: a textual ethnographic approach. Token. 2019.
52. Siddiq S, Wilson BJ, Graham ID, et al. Experiences of caregivers of children with inherited metabolic diseases: a qualitative study. Orphanet J Rare Dis. 2016;11(1):168. doi:10.1186/s13023-016-0458-2
53. Tumiene B, Graessner H. Rare disease care pathways in the EU: from odysseys and labyrinths towards highways. J Community Genet. 2021;12(2):231–239. doi:10.1002/jmg.22059-2
54. World Health Organization. WHO global strategy on people-centred and integrated health services: interim report. World Health Organization; 2015. Available from: https://apps.who.int/iris/handle/10665/155002. Accessed March 18, 2022.
55. Mula M, Cock HR. More than seizures: improving the lives of people with refractory epilepsy. Eur J Neurol. 2015;22(1):24–30. doi:10.1111/ene.12603
56. Hopkins J, Irvine F. Qualitative insights into the role and practice of Epilepsy Specialist Nurses in England: a focus group study. J Adv Nurs. 2012;68(11):2443–2453. doi:10.1111/j.1365-2648.2012.05941.x
57. Buelow J, Miller W, Fishman J. Development of an epilepsy nursing communication tool: improving the quality of interactions between nurses and patients with seizures. J Neurosci Nurs. 2018;50(2):74–80. doi:10.1097/JNN.0000000000000353
58. Hauer JM, Wolfe J. Supportive and palliative care of children with metabolic and neurological diseases. Curr Opin Support Palliat Care. 2014;8(3):296–302. doi:10.1097/SPC.0000000000000063
59. Rossi A, Hoogeveen JJ, Labout CMA, et al. A generic emergency protocol for patients with inborn errors of metabolism causing fasting intolerance: a retrospective, single-center study and the generation of www.emergencyprotocol.net. J Inherit Metab Dis. 2021;44(5):1124–1135. doi:10.1002/jimd.12386
60. Bolz-Johnson M, Kenny T, Le Cam Y, et al. Our greatest untapped resource: our patients. J Community Genet. 2021;12(2):241–246. doi:10.1007/s12386-021-00524-5
61. Grant N, Von Handorf R, Karaa A, et al. The experiences and support needs of siblings of people with mucopolysaccharidosis. Am J Med Genet A. 2021;185(11):3418–3426. doi:10.1002/ajmg.a.62460
62. Dannenberg M, Mengoni SE, Gates B, et al. Self-management interventions for epilepsy in people with intellectual disabilities: a scoping review. Seizure. 2016;41:16–25. doi:10.1016/j.seizure.2016.06.022
63. Costa AM, Marchiò M, Bruni G, et al. Evaluation of E-health applications for paediatric patients with refractory epilepsy and maintained on ketogenic diet. Nutrients. 2021;13(4):1240. doi:10.3390/nu13041240
64. Bradley PM, Lindsay B, Fleeman N. Care delivery and self management strategies for adults with epilepsy. Cochrane Database Syst Rev. 2016;2(2):CD006244. doi:10.1002/14651858.CD006244.pub3
65. Fleeman N, Bradley PM. Care delivery and self-management strategies for children with epilepsy. Cochrane Database Syst Rev. 2018;3(3):CD006245. doi:10.1002/14651858.CD006245.pub4
66. Michaelis R, Tang V, Wagner JI, et al. Cochrane systematic review and meta-analysis of the impact of psychological treatments for people with epilepsy on health-related quality of life. Epilepsia. 2018;59(2):315–332. doi:10.1111/epi.13989
67. Loeber JG, Platis D, Zetterström RH, et al. Neonatal screening in Europe revisited: an ISNS perspective on the current state and developments since 2010. Int J Neonatal Screen. 2021;7(1):15. doi:10.3390/ijns7010015
71. Brimble E, Ruzhnikov MRZ. Metabolic disorders presenting with seizures in the neonatal period. Semin Neurol. 2020;40(2):219–235. doi:10.1055/s-0040-1705119

72. Falsaperla R, Sciuto L, La Spina L, et al. Neonatal seizures as onset of Inborn Errors of Metabolism (IEMs): from diagnosis to treatment. A systematic review. Metab Brain Dis. 2021;36(8):2195–2203. doi:10.1007/s11011-021-00798-1

73. Raga S, Specchio N, Rheims S, et al. Developmental and epileptic encephalopathies: recognition and approaches to care. Epileptic Disord. 2021;23(1):40–52. doi:10.1684/epid.2021.1244

74. Reger KL, Hughes-Scalise A, O’Connor MA. Development of the transition-age program (TAP): review of a pilot psychosocial multidisciplinary transition program in a level 4 epilepsy center. Epilepsy Behav. 2018;89:153–158. doi:10.1016/j.yebeh.2018.10.021

75. Geerlings RP, Aldenkamp AP, de With PH, et al. Transition to adult medical care for adolescents with epilepsy. Epilepsy Behav. 2015;44:127–135. doi:10.1016/j.yebeh.2014.12.041

76. Pérez-López J, Ceberio-Hualde L, García-Morillo JS, et al. Clinical characteristics of adult patients with inborn errors of metabolism in Spain: a review of 500 cases from university hospitals. Mol Genet Metab Rep. 2017;10:92–95. doi:10.1016/j.ymgmr.2017.01.011

77. Sechi A, Fabbro E, Langelveld M, et al. Education and training in adult metabolic medicine: results of an international survey. JIMD Rep. 2019;49(1):63–69. doi:10.1002/jmd2.12044

78. Potter BK, Chakraborty P, Kronick JB, et al. Achieving the “triple aim” for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework. Genet Med. 2013;15(6):415–422. doi:10.1038/gim.2012.153

79. Murphy E. Medical problems in obstetrics: inherited metabolic disease. Best Pract Res Clin Obstet Gynaecol. 2015;29(5):707–720. doi:10.1016/j.bpobgyn.2015.04.006

80. Viale L, Alloyet J, Cheong-See F, et al. Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta-analysis. Lancet. 2015;386(10064):1845–1852. doi:10.1016/S0140-6736(15)00045-8

81. Grunauer M, Mikesell C, Bustamante Callejas G, et al. Primary palliative care integrated model in paediatric ICU: an international cross-sectional study. BMJ Support Palliat Care. 2021;bmjspcare-2020-002627. doi:10.1136/bmjspcare-2020-002627

82. Hoell JI, Warsmann J, Distelmaier F, et al. Challenges of palliative care in children with inborn metabolic diseases. Orphanet J Rare Dis. 2018;13(1):112. doi:10.1186/s13023-018-0868-5

83. Hoell JI, Warsmann J, Gagnon G, et al. Palliative care for children with a yet undiagnosed syndrome. Eur J Pediatr. 2017;176(10):1319–1327. doi:10.1007/s00431-017-2991-z

84. Jones BL, Contro N, Koch KD. The duty of the physician to care for the family in pediatric palliative care: context, communication, and caring. Pediatrics. 2014;133(Suppl 1):S8–S15. doi:10.1542/peds.2013-3608C

85. Friedel M, Brichard B, Fonteyne C, et al. Building bridges, paediatric palliative care in Belgium: a secondary data analysis of annual paediatric liaison team reports from 2010 to 2014. BMC Palliat Care. 2018;17(1):77. doi:10.1186/s12904-018-0324-2

86. Petropoulos MC, Bonaiuto K, Currier J, et al. Practical aspects of childhood epilepsy. BMJ. 2019;367:l6096. doi:10.1136/bmj.l6096

87. Walkowiak D, Domaradzki J. Needs assessment study of rare diseases education for nurses and nursing students in Poland. Orphanet J Rare Dis. 2020;15(1):167. doi:10.1186/s13023-020-01432-6

88. Ramalle-Gómar E, Ruiz E, Quiriones C, et al. General knowledge and opinion of future health care and non-health care professionals on rare diseases. J Eval Clin Pract. 2015;21(2):198–201. doi:10.1111/jep.12281

89. Vandeborne L, van Overbeeke E, Dooms M, et al. Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium. Orphanet J Rare Dis. 2019;14(1):99. doi:10.1186/s13023-019-1075-8

90. Pavan S, Rommel K, Mateo Marquina ME, et al. Clinical practice guidelines for rare diseases: the Orphanet database. PLoS One. 2017;12(1):e0170365. doi:10.1371/journal.pone.0170365

91. Huemer M, Diodato D, Martineilli D, et al. Phentype, treatment practice and outcome in the cobalamin-dependent remethylation disorders and MTHFR deficiency: data from the E-HOD registry. J Inherit Metab Dis. 2019;42(2):333–352. doi:10.1002/jimd.12041